TASE:LCTX

Lineage to Present at 2024 BIO International Convention

Retrieved on: 
목요일, 5월 30, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Therapy, San Diego Convention Center

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4th, 2024, at 2:30pm in Theater 3.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4th, 2024, at 2:30pm in Theater 3.
  • Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage’s novel pipeline of cell therapy transplant programs.
  • The BIO International Convention is the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Retrieved on: 
화요일, 5월 21, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Physical medicine and rehabilitation, Organization, SCI, Clinical trial, University, Therapy, New Jersey Medical School, Person, Neurosurgery, BCI, Rehabilitation, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").
  • “Through our initiatives to raise awareness and increase collaboration in the field of spinal cord injury, we have encountered an enthusiastic response to this conference from a diverse and innovative group of companies and other stakeholders.
  • “We are excited to add a BCI-focused clinical session this year with the inclusion of Neuralink and several additional corporate presenters.
  • , Chief Medical Officer, Kessler Foundation, Professor of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
목요일, 5월 9, 2024
Biotechnology, Health, Clinical Trials, AMD, Ophthalmology, City, Regenerative medicine, Research, Spinal cord, NanoString Technologies, Roche, MD, Doctor of Philosophy, Partnership, Conference, Trial of the century, Webcast, Corporate development, Beckman Research Institute, CIRM, DVM, Patient, Lineage, Geographic atrophy, Madrona Venture Group, Expense, RPE, Therapy, Delivery, G&A, Partner, Interest, Fine chemical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.
  • “The quarter was highlighted by significant milestones and data updates on our lead program,” stated Brian M. Culley, Lineage CEO.
  • Under this new agreement, Lineage will provide additional clinical, technical, training and manufacturing services that further support the ongoing advancement and optimization of the OpRegen program.
  • Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
월요일, 5월 6, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Research, Genetics, Science, Clinical Trials, AMD, Patient, Cell, MM2, Geographic atrophy, MD, Doctor of Philosophy, OCT, Lineage, Paratriathlon, Degenerative disease, RPE, Atrophy, Therapy, Visual impairment, ELM

The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD.
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Retrieved on: 
목요일, 5월 2, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Therapy, Webcast, Interest

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets.
  • Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.
  • Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Retrieved on: 
화요일, 4월 30, 2024
Research, Surgery, Public Relations, Investor Relations, Communications, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, SCI, Regenerative medicine, Conference, CIRM, Caregiver, Multimedia, Clinical trial, Therapy, Organization, Person, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) , to support the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) , to support the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").
  • The 2nd SCIIS builds upon a successful inaugural event held in 2023 and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
  • View the full release here: https://www.businesswire.com/news/home/20240430502008/en/
    “This conference was created to foster engagement and collaboration, as well as to bring innovation and modernization to approaches and treatments for spinal cord injury.
  • “In certain rare conditions, raising investor awareness can lead to greater investment, which can help to accelerate new treatments.

Lineage Announces Changes to Board of Directors

Retrieved on: 
월요일, 4월 29, 2024
Biotechnology, Health, Stem Cells, Mallinckrodt, Sale, University, General counsel, Economics, Compensated emancipation, Audit committee, PJT Partners, Bachelor of Arts, Therapy, Senior advisor, Asterias, Management

Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.

Key Points: 
  • Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.
  • Effective as of April 27, 2024, Michael H. Mulroy, J.D., has been appointed by the Board of Directors to serve as the Chairman of the Board of Directors.
  • “Al was exceptionally committed to Lineage and its shareholders, and brought great innovation, leadership, and dedication to others to his work.
  • He previously served as Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc.

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Retrieved on: 
월요일, 4월 1, 2024
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, Stem cell, B cell, Regenerative medicine, Agriculture, Global health, Lineage, Madrona Venture Group, Duke University, Beckman Research Institute, City, Columbia University, University, NanoString Technologies, Fierce, Doctor of Philosophy, Investment, Therapy, Microbiology, Partner, Corporate development, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
  • Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
  • “We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
  • Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Retrieved on: 
월요일, 3월 18, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, Organization, Cell, Regenerative medicine, Caregiver, Paralysis, Lineage, Quality of life, Clinical trial, Therapy, Multimedia, SCI, Human, Person, Pharmaceutical industry

The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).

Key Points: 
  • The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
  • The 2nd SCIIS will be held on June 26 and 27, 2024 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
  • "Our aim at Lineage is to improve recovery and mobility by replacing the cells which are destroyed following a spinal cord injury.
  • This event will bring together both public and private companies developing new treatment options for people with spinal cord injury, alongside leaders in the spinal cord injury medical and advocacy communities.

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
수요일, 3월 13, 2024
Stem Cells, Biotechnology, Health, Philanthropy, Pharmaceutical, Optical, Research, Genetics, Foundation, Science, Clinical Trials, Geographic atrophy, Patient, Visual impairment, Doctor of Philosophy, MD, Hyatt Regency Seattle, Therapy, RPE, AMD, Cell

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit .

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit .
  • The meeting will be held May 3, 2024, at the Hyatt Regency Seattle, and is jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” will include anatomical and functional data from long-term follow-up in 10 of 12 patients and will be presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.